Novavax Inc (WBO:NVAX)
€ 9.276 -0.09 (-0.96%) Market Cap: 1.49 Bil Enterprise Value: 734.28 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 47/100

Novavax Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 01:20PM GMT
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Good morning. I'm Eric Joseph, senior biotech analyst at JPMorgan. And our next presenting company this morning is Novavax, and it's my pleasure to welcome and introduce Stan Erck and Greg Glenn, CEO -- CEO, Stan Erck and Head of R&D, Greg Glenn, to tell us a little bit about the company.

Just a quick formatting note. There is a Q&A session after the presentation. So to submit a question, just click the blue "Ask a Question" button, and I can submit it or ask it on your behalf, or you can e-mail me at [email protected].

So with that, Stan, let me pass it over to you for the presentation.

Stanley Charles Erck
Novavax, Inc. - President, CEO & Director

Thank you, Eric. And good morning, and thanks for the opportunity to present today. If we can move on to Slide 3, that would be great. And we'll talk about the agenda. So in the next 20 minutes or so, we will discuss where we are today and where we're going this year. I'll take you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot